Is there a link between cellular senescence and multiple sclerosis (MS) progression? Several presentations at this year’s European Committee for Treatment and Research in Multiple Sclerosis 2025 (ECTRIMS 2025) conference, which ends today in Barcelona, addressed this question.
Neushen Therapeutics Inc. has patented NLRP3 inflammasome inhibitors reported to be useful for the treatment of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis and Huntington’s disease.
The FDA has awarded orphan drug designation to Cure Rare Disease’s CRD-003 for the treatment of limb-girdle muscular dystrophy type R9 (LGMD2i/R9), a congenital muscular dystrophy caused by biallelic mutations in the FKRP gene.
The Royal College of Psychiatrists in the U.K. has published its first-ever guidance to support research into psychedelic drugs as therapies for conditions including treatment-resistant depression, substance abuse disorders and posttraumatic stress disorder, saying that in a fast-moving field there is a risk of jumping ahead of the evidence.
Humanwell Healthcare (Group) Co. Ltd. has divulged P2X purinoceptor 7 (P2RX7; P2X7) antagonists reported to be useful for the treatment of pain, inflammatory, neurological and immunological disorders.
Miralogx LLC and Mira Pharmaceuticals Inc. have jointly disclosed new cannabinoid analogues acting as monoamine oxidase-A (MAO-A) and/or MAO-B inhibitors reported to be useful for the treatment of epilepsy, anxiety disorders and pain.
Chinese Academy of Sciences researchers have patented heptanoate compounds reported to be useful for the treatment of amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s and Huntington’s disease.
Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by the loss of function of the maternally inherited ubiquitin E3 ligase UBE3A gene. AS is characterized by severe symptoms, including lack of speech, epilepsy, developmental and motor skills delays, sleep disturbances and cognitive impairment. Currently, no treatments are available for this disease.
NS Pharma Inc.’s NS-051 (NCNP-04) has been awarded orphan drug designation by the FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to exon 51 skipping.
Experts agree that the earlier Alzheimer's disease is detected, the sooner action can be taken. And so, the key to preventing deterioration is identifying the most effective early biomarkers, those that can spot the disorder and help halt its progression. Recent advances in the field have pushed a new era of early detection through blood-based biomarkers and personalized medicine strategies based on each patient’s genetic, immunological and clinical profile.
RSS
